Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 349

Related Citations for PubMed (Select 19483670)

1.

Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer.

Apple SK, Lowe AC, Rao PN, Shintaku IP, Moatamed NA.

Mod Pathol. 2009 Sep;22(9):1151-9. doi: 10.1038/modpathol.2009.82. Epub 2009 May 29.

2.

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.

D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.

Am J Surg Pathol. 2010 Apr;34(4):575-81. doi: 10.1097/PAS.0b013e3181d65639.

PMID:
20216378
3.
4.
5.

Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens.

Susini T, Bussani C, Marini G, Nori J, Olivieri S, Molino C, Bianchi S, Vezzosi V, Paglierani M, Giachi M, Borrani E, Scarselli G.

Gynecol Oncol. 2010 Feb;116(2):234-9. doi: 10.1016/j.ygyno.2009.10.067. Epub 2009 Nov 17.

PMID:
19919879
6.

SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients.

D'Alfonso TM, Liu YF, Chen Z, Chen YB, Cimino-Mathews A, Shin SJ.

J Clin Pathol. 2013 May;66(5):409-14. doi: 10.1136/jclinpath-2012-201270. Epub 2013 Feb 5.

PMID:
23386665
7.
8.

Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.

Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, Tobiume M, Zennami K, Katsuda R, Honda N.

Oncol Rep. 2008 Jan;19(1):57-63.

PMID:
18097576
9.

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer.

Bozzetti C, Nizzoli R, Guazzi A, Flora M, Bassano C, Crafa P, Naldi N, Cascinu S.

Ann Oncol. 2002 Sep;13(9):1398-403.

10.

Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases.

Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ.

Mod Pathol. 2008 Apr;21(4):363-8. doi: 10.1038/modpathol.3801021. Epub 2008 Feb 1.

11.

Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.

Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ.

Histopathology. 2006 Feb;48(3):258-67.

PMID:
16430472
12.

HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.

Beatty BG, Bryant R, Wang W, Ashikaga T, Gibson PC, Leiman G, Weaver DL.

Am J Clin Pathol. 2004 Aug;122(2):246-55.

13.
15.

Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer.

Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Roka S, Bachleitner T, Kandioler D, Steger G, Mittlböck M, Jakesz R.

Wien Klin Wochenschr. 2004 Jan 31;116(1-2):26-31.

PMID:
15030120
17.

Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.

Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ.

Am J Surg Pathol. 2008 Nov;32(11):1721-6. doi: 10.1097/PAS.0b013e31817dc3a6.

PMID:
18769331
18.

Accurate prediction of the amount of in situ tumor in palpable breast cancers by core needle biopsy: implications for neoadjuvant therapy.

El-Tamer M, Axiotis C, Kim E, Kim J, Wait R, Homel P, Braverman A.

Ann Surg Oncol. 1999 Jul-Aug;6(5):461-6.

PMID:
10458684
19.

Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.

Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B.

Histopathology. 2009 Jan;54(2):248-53. doi: 10.1111/j.1365-2559.2008.03185.x.

PMID:
19207950
20.

Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing.

Luftner D, Henschke P, Kafka A, Anagnostopoulos I, Wiechen K, Geppert R, Stein H, Wernecke KD, Kreienberg R, Possinger K.

Int J Biol Markers. 2004 Jan-Mar;19(1):1-13.

PMID:
15077921
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk